The Effectiveness of Kinesiologic Taping in Patients With Knee Rheumatoid Arthritis

NCT07253766 | Completed

• 2 other identifiers: E53938333-050-45035Istanbul Rumeli University
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if kinesiologic taping works to treat individuals with Rheumatoid Arthritis. The main questions it aim to answer:

• Is kinesiologic taping applied to the knee joint an effective treatment for pain, mobility, and kinesiophobia in individuals diagnosed with rheumatoid arthritis?
• Which is more effective? Kinesiologic taping or non-therapeutic sham taping? Which is better for pain, functional capacity, kinesiophobia and disease activity? Researchers will compare kinesiologic taping and non-therapeutic sham taping . Patients will be randomly divided into groups. The first group of patients was treated with sham taping, and the application period was applied consecutively for 4 weeks, with a minimum interval of 3 days and a maximum interval of 5 days. Group 2 patients underwent kinesiological taping, with the application period ranging from 3 to 5 days per week for 4 consecutive weeks.

Conditions

Rheumatoid Arthritis; Pain; Kinesiophobia

Keywords

rheumatoid arthritis; pain; kinesiophobia; kinesiologic taping

Outcome Measures

Primary Outcomes (4)

• Visual Analog Scale

  A Visual Analog scale(VAS) was used to assess pain intensity. Participants were asked to rate their perceived pain on a 10-cm horizontal line, where 0 cm indicates "no pain" and 10 cm indicates "worst pain imaginable." The participants marked a point on the line that best represented their pain intensity at rest and during activity. The distance (in centimeters) from the "no pain" end to the participant's mark was measured and recorded as the VAS score.

  Four Weeks

• Tampa Kinesiophobia Scale

  Kinesiophobia was assessed using the Tampa Scale for Kinesiophobia (TSK), a self-report questionnaire designed to measure fear of movement or re-injury. The scale consists of 17 items, each rated on a 4-point Likert scale ranging from 1 ("strongly disagree") to 4 ("strongly agree"). Higher scores indicate a greater degree of kinesiophobia, with a total score range between 17 and 68 points.

  Four Weeks

• Timed up and Go test

  Functional mobility was assessed using the Timed Up and Go (TUG) test, a simple and reliable measure of dynamic balance and mobility. Participants were instructed to rise from a standard chair, walk three meters, turn around, walk back, and sit down at their normal walking speed. The time taken to complete the task was measured in seconds using a stopwatch. Shorter completion times indicate better functional mobility.

  Four weeks

• Disease Activity

  Disease activity was evaluated using the Disease Activity Score-28 (DAS28), which incorporates the number of tender and swollen joints (out of 28), the erythrocyte sedimentation rate (ESR), and the patient's global health assessment (GH) on a 100-mm Visual Analog Scale. The DAS28 score was calculated according to the standard formula, with values below 2.6 indicating remission, 2.6-3.2 low disease activity, 3.2-5.1 moderate activity, and above 5.1 high disease activity. This index is widely used to monitor disease progression and treatment response in patients with rheumatoid arthritis.

  Four weeks

Study Arms (2)

kinesiologic taping group

EXPERIMENTAL

Kinesiology tape will be applied to the knee joint.

Other: kinesiologic taping

Sham taping

SHAM COMPARATOR

Non-therapeutic sham taping will be applied to the knee joint

Other: sham taping

Interventions

kinesiologic taping OTHER

The taping will be applied to the knee joint for 4 weeks.

kinesiologic taping group

sham taping OTHER

The non-therapeutic taping will be applied to the knee joint for 4 weeks.

Sham taping

Eligibility Criteria

• Age: 45 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Patients aged 45 to 60
• Patients diagnosed with acute or chronic rheumatoid arthritis;
• Patients whose rheumatic medication protocol has not changed in the last 3 months; -Patients who do not smoke, drink alcohol or use drugs;
• Patients who have no vision, hearing or speech problems;
• Patients who are not amputees;
• Patients who can walk independently.

You may not qualify if:

• individuals over the age of 61;
• individuals with neurological disorders, severe chronic obstructive pulmonary disease, liver or kidney failure, malignancies, uncontrolled diabetes mellitus, major psychiatric disorders, or pregnancy; and those with concomitant conditions that could cause balance problems.
• Pregnant and breastfeeding women;
• individuals who had undergone surgery in the last few months;
• patients with loss of cooperation (e.g., those diagnosed with dementia or Alzheimer's disease) were also excluded from the study.

Sponsors & Collaborators

• Istanbul Rumeli University: lead

Study Sites (1)

Istanbul Rumeli University

Istanbul, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid; Pain; Kinesiophobia

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Phobic Disorders; Anxiety Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assist.Prof

Model Details: Randomized controlled trial

Study Record Dates

• First Submitted: September 18, 2025
• First Posted: November 28, 2025
• Study Start: November 1, 2024
• Primary Completion: April 1, 2025
• Study Completion: May 1, 2025
• Last Updated: November 28, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)